ArticleBMC research notes2026
A comparative study of molecular characteristics of pathogenic and uncertain significance variants of BRCA1/2 in Chinese breast cancer patients.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAlthough many studies focus on breast cancer patients carrying pathogenic or likely pathogenic variants (P/LPVs) of the breast cancer susceptibility gene (BRCA), the impact of variants of uncertain significance (VUS) on breast cancer remains unclear. This study aims to analyze the tumor biological characteristics of different mutation types of the BRCA in the Shenzhen population.
results(1) Among the patients included based on the genetic high-risk breast cancer assessment guidelines, the detection rate of BRCA mutations reached 21.2% (87/411) ; (2) Pathogenic variant c.5239 C > T in the BRCA1 was detected in 3 cases, while pathogenic variants c.3109 C > T and c.8951 C > G in the BRCA2 were each detected in 3 cases; (3) In breast cancer patients carrying BRCA and BRCA1 mutations, the negative rates of estrogen receptor and progesterone receptor in the pathogenic or likely pathogenic variants group are higher than those in the variants of uncertain significance group; (4) The types of BRCA mutations (P/LPVs versus VUS) were correlated with the expression levels of estrogen receptor and progesterone receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.